SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022

BACKGROUND: Omicron subvariant BA.2 circulation is rapidly increasing globally. AIM: We evaluated the neutralising antibody response from vaccination or prior SARS-CoV-2 infection against symptomatic infection by BA.2 or other variants. METHODS: Using 50% plaque reduction neutralisation tests (PRNT(...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Samuel MS, Mok, Chris Ka Pun, Chan, Karl CK, Ng, Susanna S, Lam, Bosco HS, Luk, Leo LH, Ko, Fanny W, Chen, Chunke, Yiu, Karen, Li, John KC, Chan, Ken KP, Tsang, Leo CH, Poon, Leo LM, Hui, David SC, Peiris, Malik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Centre for Disease Prevention and Control (ECDC) 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9074393/
https://www.ncbi.nlm.nih.gov/pubmed/35514306
http://dx.doi.org/10.2807/1560-7917.ES.2022.27.18.2200178

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9074393/
https://www.ncbi.nlm.nih.gov/pubmed/35514306
http://dx.doi.org/10.2807/1560-7917.ES.2022.27.18.2200178

Ejemplares similares